“Biotech industry growth is bolstered by increased R&D spending, an upswing of approved first-in-class medicines, elevated Wall Street valuations, and continued
forging of pipeline alliances with Big Pharma” - 22nd Annual Report: Top 100 Biotechnology Companies, Andrew Humphreys.
In this new infographic Biotech Outlook 2013: Top Biotechs we take a closer look at the top 25 biotechs so far in 2013 and the performance of key industries related to biotech M&A activity.
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |